Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT00769145
Phase
PHASE1
Status
Completed

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).

Study Details

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.

Key Dates

First listed
Oct 8, 2008
Start date
Oct 31, 2008
Status verified
Jul 2017
Primary completion
Aug 31, 2011
Completion
Mar 31, 2012

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab
    Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally

Primary Outcome Measure

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation. [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Bascom Palmer Eye InstituteMiamiFlorida33136-

Find similar trials in Miami, FL

By research site
Bascom Palmer Eye Institute· Miami, FL

Related Studies